Traders should not interpret this Form 144 as a negative signal; it reflects a standard tax settlement mechanism following RSU vesting, not a voluntary sale. Monitor for any additional discretionary Form 14s or Form 4s for signs of actual insider sentiment.
TVTX drugs
TVTX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 15 $40.95entry
- T+1 · 7mo ago −3.44%α −3.70% · $39.54
- T+5 · 7mo ago −2.10%α −3.74% · $40.09
- T+20 · 6mo ago +4.62%α −1.43% · $42.84
- T+60 · 4mo ago +38.19%α +30.06% · $56.59
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Elizabeth E. Reed, an officer of Travere Therapeutics, filed a Form 144 to report a mandatory 'sell to cover' transaction of 37,500 shares to satisfy tax withholding obligations following the vesting of performance-based restricted stock units. This is not a discretionary sale.
Key Facts
- Elizabeth E. Reed, an officer, is reporting a proposed sale of 37,500 common shares.
- The sale is a mandatory 'sell to cover' transaction to fund tax withholding obligations from vested performance restricted stock units.
- The transaction occurred on April 14, 2026, and was not a discretionary trade by the insider.
- Total value of the sale was approximately $1.54 million based on a share price of ~$41.07.
- This follows a pattern of similar non-discretionary sales by the same insider over the past few months.
Financial Impact
Approximately $1.54 million in shares to be sold, representing tax-related obligations rather than insider divestment.
Risk Factors
- Potential misinterpretation by retail investors as a discretionary insider sale, leading to unwarranted selling pressure.
- Continued pattern of tax-related sales could signal upcoming vesting events that may periodically increase share supply.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001193125-26-155628 |
| Document: 0001193125-26-155628-index.html | 0001193125-26-155628 |
| Document: 0001193125-26-155628.txt | 0001193125-26-155628 |
Track record
21 reports on TVTX
8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +56.24% at T+60 after the Jun 2, 2026 report. 10 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $50.30 Now $49.70 −1.19% settles Nov 23
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $48.87 to $51.56 Now $49.70 +1.70% ▲ +5.50% +2.21% vs SPY
- Nov 3, 202613d ago Institutional Cluster Bullish 4/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Sep 17, 20268w ago Insider Cluster Bearish 4/10 Entry $62.76 to $59.44 Now $49.70 +20.81% ▲ +5.29% +6.56% vs SPY
- Jul 9, 202618w ago 8-K Neutral 2/10 Entry $56.59 to $55.28 Now $49.70 −12.18% ▼ −2.31% −1.75% vs SPY
- Jun 16, 202621w ago Insider Cluster Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 16, 202621w ago 8-K Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 12, 202622w ago 144 Neutral 2/10 Entry $52.04 to $55.15 Now $49.70 −4.50% ▲ +5.98% +5.30% vs SPY
- Jun 2, 202623w ago 8-K Bullish 6/10 Entry $42.96 to $48.57 Now $49.70 +15.69% ▲ +13.06% +16.02% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers